nps-568 has been researched along with Uremia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 12 (85.71) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gross, ML; Koleganova, N; Piecha, G; Ritz, E; Schmitt, CP | 1 |
| Caudrillier, A; Drüeke, TB; Fukagawa, M; Hamada, Y; Ivanovski, O; Joki, N; Kamel, S; Lacour, B; Maizel, J; Massy, ZA; Mentaverri, R; Nguyen-Khoa, T; Nikolov, IG; Phan, O | 1 |
| Bekeredjian, R; Gross, ML; Koleganova, N; Piecha, G; Ritz, E; Schirmacher, P; Schmitt, CP | 1 |
| Akizawa, T; Hosaka, N; Kinugasa, E; Koiwa, F; Kondo, F; Kumata, C; Mizobuchi, M; Nakazawa, A; Ogata, H | 1 |
| Ben-Dov, IZ; Dinur, M; Lavi-Moshayoff, V; Levi, R; Martin, D; Naveh-Many, T; Silver, J | 1 |
| de Vernejoul, MC; Legoupil, N; Ureña, P | 1 |
| Gohlke, P; Hadtstein, C; Nakagawa, K; Odenwald, T; Ritz, E; Roesch, F; Schaefer, F; Schmitt, CP | 1 |
| Aguilera-Tejero, E; Almaden, Y; Lopez, I; Martin, D; Mendoza, FJ; Perez, J; Rodriguez, M | 1 |
| Akizawa, T; Hatamura, I; Kinugasa, E; Koiwa, F; Koshikawa, S; Mizobuchi, M; Ogata, H; Saji, F | 1 |
| Fox, J; Furuya, Y; Ishii, H; Nagano, N; Nemeth, EF; Wada, M | 2 |
| Chin, JI; Fox, J; Miller, SC; Nagano, N; Nemeth, EF; Wada, M | 1 |
| Ritz, E; Schömig, M | 1 |
| Lewin, E; Olgaard, K | 1 |
3 review(s) available for nps-568 and Uremia
| Article | Year |
|---|---|
[Calcimimetics, mechanisms of action and therapeutic applications].
Topics: Aniline Compounds; Animals; Bone Remodeling; Calcium; Cells, Cultured; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hyperplasia; Male; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats; Receptors, Calcium-Sensing; Renal Dialysis; Risk Factors; Time Factors; Uremia | 2005 |
Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives--calcimimetics.
Topics: Aniline Compounds; Animals; Calcitonin; Calcium; Calcium-Binding Proteins; Humans; Hypercalcemia; Hypocalcemia; Parathyroid Hormone; Phenethylamines; Propylamines; Treatment Outcome; Uremia; Vitamin D | 2000 |
Prevention of uremic bone disease using calcimimetic compounds.
Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface; Treatment Outcome; Uremia | 2001 |
11 other study(ies) available for nps-568 and Uremia
| Article | Year |
|---|---|
A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia.
Topics: Aniline Compounds; Animals; Aorta; Calcinosis; Calcitriol; Calcium; Cell Proliferation; Endothelium, Vascular; Gene Expression Regulation; Muscle, Smooth, Vascular; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Receptors, Calcium-Sensing; Renal Insufficiency; Uremia | 2009 |
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice.
Topics: Aniline Compounds; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Calcinosis; Calcium; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Kidney Failure, Chronic; Mice; Mice, Transgenic; Phenethylamines; Phosphorus; Propylamines; Receptors, Calcium-Sensing; Uremia | 2009 |
Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic.
Topics: Aniline Compounds; Animals; Biomarkers; Calcium; Capillaries; Coronary Vessels; Endothelium, Vascular; Enzyme Activation; Fibrosis; Heart; Heart Diseases; Male; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; Nephrectomy; Organ Size; Oxidative Stress; Phenethylamines; Phosphorus; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Uremia | 2009 |
Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progression.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aniline Compounds; Animals; Calcium; Cardiomyopathies; Disease Progression; Drug Therapy, Combination; Enalapril; Male; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley; Uremia | 2011 |
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.
Topics: Aniline Compounds; Animals; Gene Expression Regulation; Heterogeneous Nuclear Ribonucleoprotein D0; Heterogeneous-Nuclear Ribonucleoprotein D; Hyperparathyroidism, Secondary; Male; Parathyroid Hormone; Phenethylamines; Propylamines; Protein Processing, Post-Translational; Rats; RNA, Messenger; Uremia | 2006 |
Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats.
Topics: Acute Disease; Aniline Compounds; Animals; Blood Pressure Determination; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypotension; Injections, Subcutaneous; Male; Nephrectomy; Phenethylamines; Probability; Propylamines; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Sensitivity and Specificity; Sodium; Time Factors; Uremia | 2006 |
Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.
Topics: Aniline Compounds; Animals; Biopsy, Needle; Blood Chemical Analysis; Calcinosis; Calcitriol; Disease Models, Animal; Drug Therapy, Combination; Immunohistochemistry; Male; Nephrectomy; Phenethylamines; Probability; Propylamines; Rats; Rats, Wistar; RNA, Messenger; Sensitivity and Specificity; Survival Rate; Uremia | 2006 |
Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells.
Topics: Aniline Compounds; Animals; Apoptosis; Cyclodextrins; Hyperplasia; In Situ Nick-End Labeling; Male; Microscopy, Electron; Models, Biological; Parathyroid Glands; Phenethylamines; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Uremia | 2007 |
NPS R-568 halts or reverses osteitis fibrosa in uremic rats.
Topics: Aniline Compounds; Animals; Biomechanical Phenomena; Bone Density; Calcium; Creatinine; Femur; Fibrosis; Hyperparathyroidism; Kidney Function Tests; Male; Osteitis; Parathyroid Hormone; Phenethylamines; Propylamines; Radiography; Rats; Rats, Sprague-Dawley; Tibia; Uremia | 1998 |
Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
Topics: Aniline Compounds; Animals; Bone and Bones; Bone Density; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Doxorubicin; Humans; Hyperparathyroidism, Secondary; Male; Osteomalacia; Parathyroid Hormone; Phenethylamines; Phosphates; Propylamines; Rats; Rats, Sprague-Dawley; Uremia | 2000 |
Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.
Topics: Analysis of Variance; Aniline Compounds; Animals; Blood Urea Nitrogen; Calcium; Calcium-Binding Proteins; Creatinine; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Propylamines; Rats; Rats, Sprague-Dawley; Steroid Hydroxylases; Uremia | 2000 |